Beside Metformin: Substitute or Augment, Both Lose

what do subparagraphs (vi) and (vii) actually prohibit?

Subparagraph (vi) bars claiming a supplement replaces a drug therapy; subparagraph (vii) bars claiming it boosts one. Both sit inside 21 CFR 101.93(g)(2), FDA's ten-part test for when a structure/function claim, a lawful body-function statement, tips into an illegal disease claim. For blood sugar products the drug in question is almost always insulin or metformin, and the two subparagraphs cover opposite ends of the same positioning move: replace it, or complement it.

FDA's own wording, via the current text at eCFR, draws the line without much room to argue. A claim becomes a disease claim if the product "is a substitute for a product that is a therapy for a disease," or if it "augments a particular therapy or drug action that is intended to diagnose, mitigate, treat, cure, or prevent a disease." Neither sentence requires you to name the drug outright — implying the relationship is enough.

The practical split for a diabetes offer looks like this.

does 'works alongside your doctor's plan' fall under augmentation?

Usually yes, once the copy implies the product changes how well a named drug or drug class performs — not just how the reader feels day to day.

Vague wellness language alone rarely trips (vii) by itself. The subparagraph is triggered by a claimed effect on 'a particular therapy or drug action,' which means the copy has to point at something specific: a prescription, a drug class, or a dosage. 'Alongside your doctor's plan' with no further detail is thin evidence standing on its own — but FDA reads a whole site as one record, and a symptom list, an ingredient page, or a testimonial elsewhere on your domain routinely supplies the specificity the ad copy left out.

That's the trap in diabetes copy specifically. We checked the pattern across FDA's 2021 and 2023 diabetes letters: the augmentation claim almost never sits in the headline. It shows up in an ingredient blurb, a hashtag, or a buried testimonial, and FDA cites all three as if they were the ad itself.

does 'a natural alternative' fall under substitution?

Yes — 'alternative' sits close to the substitution language itself, and FDA doesn't need a superiority claim to apply (vi), only a replacement claim.

FTC's case against Nobetes Corp is a clean illustration, even without the FDA text. The company sold a diabetes pill and settled charges in December 2018 that barred unsubstantiated health claims, misleading free-trial terms and consumer-testimonial endorsements; FTC returned $60,791 to buyers in August 2019. 'Alternative' framing doesn't need to claim the product beats the drug — it only needs to claim the product does the drug's job.

Softening the word to 'natural' doesn't change the analysis, because FTC's guidance treats the disclaimer problem as separate from the vocabulary problem. The FTC Health Products Compliance Guidance states that a DSHEA disclaimer — the required no-FDA-evaluation notice — "doesn't negate the explicit and directly contradictory claim that the product treats diabetes." 'Natural' sitting next to that disclaimer buys nothing if the surrounding copy still reads as treatment.

is there any framing that avoids both criteria?

Yes, but narrowly.

FDA wrote out the fix itself, in the same breath it wrote out the violation. Per its 2000 final rule, the agency held that "use as part of your diet when taking insulin to help maintain a healthy blood sugar level" is a disease claim, because naming the drug alongside a diabetes-diet purpose implies a treatment relationship. Strip the drug reference and you get the version FDA accepts: use as part of your diet to help maintain a healthy blood sugar level. Delete the drug name, and the implication disappears with it.

That fix only covers your ad copy, though, not the rest of the funnel. FDA has repeatedly aggregated a product's blog posts, ingredient pages and social accounts into a single intended-use record, so a landing page that drops 'insulin' cleanly can still fail if your blog or your old Instagram caption names it three clicks away. And even a claim that clears FDA's disease-claim test still needs FTC-level clinical substantiation behind it — a federal court held in FTC v. Wellness Support Network that ingredient-level studies don't substitute for a trial on the marketed formula, reasoning that ingredients can interact in ways a single-ingredient study can't capture.

how did fda apply these to real diabetes supplement copy?

FDA didn't wait for complaints to build a diabetes enforcement record — it ran a coordinated sweep. On September 7, 2021, FDA's Center for Food Safety and Applied Nutrition issued ten warning letters in a single day, all charged "Unapproved New Drugs/Misbranded," to a mix of ordinary supplement sellers: Lysulin, Pharmaganics, Metamune, Ar-Rahman Pharm, Holistic Healer & Wellness Center, Phytag Labs, Live Good, Radhanite (Curalife), Aceva and Nuturna International. We read FDA's warning-letter index directly rather than take the count on faith, and it still returns 146 hits for the plain word 'diabetes' — the highest volume of any niche in this fact set. A coordinated same-day sweep like that is how this vertical gets enforced: the risk isn't being singled out, it's being caught in a keyword search.

Lysulin's letter (MARCS-CMS 614517, September 7, 2021) shows how thin the copy can be and still count as evidence. FDA quoted the brand's own Instagram hashtag string — tags covering type-2-diabetes, diabetes care and insulin resistance — and a customer testimonial reporting an HbA1c drop from 10.5% to 9.5%, both cited as separate proof of intended use. FDA also noted it reviewed the same websites the same month as the FTC, in August 2021 — two agencies, one set of properties.

Organic social content is not a safe zone, in other words. A hashtag string, a customer's lab result posted in a comments section, an old blog post — FDA has treated all of them as part of the same labeling record as the sales page.

what happens when the comparison appears only in a testimonial?

It counts exactly the same — FDA treats a customer's words as the advertiser's own claim.

The clearest example is FDA's letter to Hekma Center, which reproduced a full case-study page describing a customer who cut his Omformin dose from four and a half pills a day to one, closing with the brand's own congratulations for the customer overcoming diabetes entirely. None of that description came from a copywriter — it came from the buyer, or from whoever wrote up the buyer's story — and FDA cited it anyway as evidence the product substituted for a diabetes drug.

Lysulin's testimonial worked the same way: a customer's reported HbA1c change became independent proof of intended use, filed right alongside the brand's own product claims. Your review widget doesn't get to call itself just user-generated content once a regulator is reading the page as one document.

how should a lander reference existing treatment, if at all?

Generally, don't name it at all.

FDA's insulin example is the template: drop the drug's name, keep the maintenance language, and the same sentence that was a disease claim with 'insulin' in it becomes a lawful structure/function claim without it. Extend the same logic to metformin, sulfonylureas or any other blood-sugar drug class — the fix isn't a better euphemism, it's removing the referent entirely.

That only handles the drug reference in your own copy. FTC's substantiation floor sits underneath it regardless of what the ad names: a randomized, controlled human clinical trial on the marketed formula, not a citation to a study on one ingredient, and not a customer's HbA1c chart standing in for a trial.

One thing we could not verify for this niche: who actually buys blood-sugar supplements — age distribution, how many are already on metformin or insulin, how many have tried and abandoned a supplement before. CDC's diabetes statistics pages and NIDDK were both unreachable when we checked, so treat any buyer-demographic claim in this space as unverified until you've pulled the CDC National Diabetes Statistics Report directly.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Absentmindedness Is Allowed. Memory Loss Is Not., Prevagen: Seven Years of Litigation Over a Chart, Geniux: 36 Affiliate Networks Inside One FTC Case, Where the Sleep Apnea Disclaimer Has to Sit, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.